All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Featured:
In patients with acute myeloid leukemia (AML) undergoing induction, presence and persistence of infections can delay antineoplastic therapy which can affect overall survival. The safety and efficacy of CLT-008, an off-the-shelf human allogeneic myeloid progenitor cell, as a measure to reduce infections after induction chemotherapy for patients with AML was investigated in a randomized controlled phase II study. At the 23rd Congress of the European Hematology Association, on behalf of colleagues, Pinkal Desai, Weill Cornell Medicine, presented the results of this phase II study.
Ninety-four patients with newly diagnosed AML were randomized 1:1 to receive standard 7 + 3 (cytarabine and an anthracycline) induction chemotherapy with granulocyte-colony stimulating factor (G-CSF, starting on Day 14 [control]) alone (n = 46, median age = 64 years) or CLT-008 (7.5 x 106 cells/kg on day 9) plus G-CSF (n = 48). The primary endpoint of the study was days in a febrile episode from Day 9–28. The secondary endpoints of the study were the incidence of infections, therapeutic use of antimicrobials, hematologic recovery and morbidity & mortality.
In summary, the incidence of infections, use of antibacterial agents and days in hospital were decreased in patients receiving CLT-008. The speaker, Dr. Desai in an interview with the AGP, stated that the results of this phase II study are significant as CLT-008 was able to reduce infections by 73% which represents an unmet need in AML induction that provides supportive care in order to ensure elderly AML patients can go through AML induction therapy. Dr. Desai further concluded that “myeloid progenitors may provide a new option to reduce infections in AML patients undergoing induction therapy”.
References